Author Affiliations: Departments of Pathology (Drs Zhang and Yang) (firstname.lastname@example.org) and Gynecologic Oncology and Reproductive Medicine (Dr Sood), University of Texas MD Anderson Cancer Center, Houston.
In Reply: Drs Buerkle and Tempfer asked whether differences in progression-free survival and primary chemotherapy response between BRCA1 - and BRCA2 -mutated cases could be the result of unbalanced distribution of disease stages and extent of cytoreduction. The distribution of cytoreduction outcomes between BRCA1 - and BRCA2 -mutated cases was similar (P = .94; Table 1 in the article). Although there was an apparent difference in the proportion of stage IV cases between BRCA1- and BRCA2- mutated cases, it was not significant (P = .28).
Zhang W, Yang D, Sood AK. BRCA1 and BRCA2 Mutations in Ovarian Cancer—Reply. JAMA. 2012;307(4):359-361. doi:10.1001/jama.2012.10